The incretin effect was first described as an anomaly. Glucose given orally produced a substantially larger insulin response than the same quantity of glucose given intravenously. Something in the gut was signalling the pancreas in advance of the glucose arriving, and that signal accounted for a large fraction of the total insulin response to a meal.
Identifying the responsible hormones, and then engineering peptides that reproduce their action with a usable duration, has become the most productive line of metabolic peptide research to date.
This article describes published research. All products supplied by North Specs Labs are Research Use Only and are not for human or veterinary use.
The two incretin hormones
Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino-acid peptide released from K cells in the proximal small intestine. It was the first incretin identified.
Glucagon-like peptide-1 (GLP-1) is produced by L cells, more distally, from the proteolytic processing of proglucagon. It is the more studied of the two, with a broad set of actions: it potentiates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts at receptors in the hypothalamus and brainstem involved in satiety.
The glucose dependence is mechanistically important. Both peptides potentiate insulin secretion only when glucose is elevated, which is why incretin-based approaches do not drive insulin release in the way that sulfonylureas do.
The half-life problem
Native GLP-1 has a circulating half-life of roughly one to two minutes. Dipeptidyl peptidase-4 (DPP-4) cleaves the peptide at the penultimate alanine, and renal clearance removes the rest.
Two strategies followed. One was to inhibit DPP-4 with a small molecule, raising endogenous incretin levels modestly. The other was to build a peptide that resists cleavage, which is where most of the interesting chemistry has happened.
The design approaches that emerged:
- Substitution at the DPP-4 cleavage site. Replacing the alanine at position 8 blocks the primary route of degradation.
- Fatty-acid acylation. Attaching a lipid chain promotes reversible albumin binding, creating a circulating depot and slowing renal clearance. This is the mechanism behind weekly dosing.
- Backbone modification. Exendin-4, isolated from Gila monster venom, is a naturally DPP-4-resistant GLP-1 receptor agonist that provided an early template.
Single-receptor agonists
The first generation targeted the GLP-1 receptor alone. This class established that sustained receptor agonism produced glycaemic improvement and, unexpectedly at the time, substantial weight reduction. The weight effect was initially considered a secondary observation and became the dominant research interest.
Semaglutide, an acylated GLP-1 receptor agonist engineered for extended albumin binding, is the most studied compound in this class and the reference ligand for much current laboratory work.
Dual agonists
The GIP receptor was, for a long time, considered a dead end. GIP's insulinotropic action appeared blunted in type 2 diabetes, and there was disagreement about whether GIP receptor agonism or antagonism would be beneficial for body weight, since GIP has actions in adipose tissue that could plausibly favour fat storage.
Tirzepatide, a single peptide with agonist activity at both GIP and GLP-1 receptors, was the test of that question. It produced greater glycaemic and weight effects than GLP-1 receptor agonism alone in head-to-head clinical comparison.
Why combined agonism outperforms single-receptor action is still debated. Candidate explanations include complementary central nervous system signalling through distinct receptor populations, GIP receptor effects on nausea tolerability permitting higher effective exposure, and direct GIP action in adipose tissue improving lipid handling. The mechanistic question remains genuinely open, which is what makes it an active research area rather than a settled one.
Triple agonists
Retatrutide extends the approach to a third receptor, the glucagon receptor. Glucagon is counter-intuitive as a target in metabolic disease, since it raises blood glucose. But glucagon receptor agonism also increases energy expenditure and promotes hepatic lipid oxidation. The design premise is that adding controlled glucagon receptor activity to incretin agonism increases energy expenditure while the incretin components suppress appetite and control the glycaemic consequence.
The engineering problem is ratio. Each receptor requires a specific relative potency, and the therapeutic window depends on getting those ratios right rather than on maximising activity at any one receptor. This is the central technical challenge in the current generation of these molecules.
Amylin and other directions
Amylin, co-secreted with insulin from beta cells, acts on satiety and gastric emptying through a distinct receptor system. Long-acting amylin analogues, and combinations pairing amylin agonism with GLP-1 receptor agonism, are an active parallel line of research.
Other directions include oral formulations using absorption enhancers, peptide-conjugate approaches delivering a nuclear hormone payload to incretin-receptor-expressing cells, and antagonist rather than agonist approaches at the GIP receptor, which remains a live scientific disagreement.
What laboratory work looks like
Incretin peptides are used across several assay types:
Receptor binding and activation. Competition binding against a labelled reference ligand, and cAMP accumulation assays in cells expressing the receptor of interest, characterise affinity and potency. Multi-receptor compounds require parallel assay at each receptor to establish the ratio.
Beta-cell function. Glucose-stimulated insulin secretion in isolated islets or beta-cell lines tests the glucose-dependence of the insulinotropic effect.
Signalling bias. GLP-1 receptor agonists differ in their relative engagement of G-protein signalling versus beta-arrestin recruitment and receptor internalisation. Bias appears to influence sustained response, and characterising it requires assays that separate the pathways.
Stability and degradation. Incubation with DPP-4 or plasma, followed by LC-MS analysis of intact peptide over time, quantifies the resistance that the design was intended to confer.
Reference material quality
Incretin analogues are long, structurally complex peptides, often with acylation. Several failure modes matter experimentally.
Incomplete acylation produces a mixture of acylated and non-acylated peptide with different albumin binding and therefore different apparent potency in any assay involving serum. Deletion sequences from incomplete coupling in a long synthesis can retain partial receptor activity and shift a dose-response curve. Oxidation at methionine residues alters receptor engagement. Residual trifluoroacetate affects cell viability in sensitive lines.
A certificate of analysis identifying the batch, the analytical method and the purity result is the minimum for work where the dose-response relationship is the measurement. For multi-receptor compounds, where the ratio of potencies is the property under study, material quality is not a background concern but a direct determinant of the result.
North Specs Labs supplies research-grade peptides to qualified researchers, laboratories and research institutions. All products are Research Use Only and are not for human consumption or veterinary use.
North Specs separates research education from product claims. Readers should review primary literature and institutional requirements before designing laboratory work.